ArticleBMC medical imaging2026
Prognostic value of [
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the prognostic value of [
methodsThis retrospective study enrolled 43 patients treated with anti-PD-1 inhibitors plus chemotherapy between March 2022 and June 2025. We analyzed pre-therapeutic maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Subgroup analyses evaluated early metabolic changes in patients with follow-up PET/CT (n = 15) and metabolic trajectory in those with initial staging PET/CT (n = 19).
resultsForty-three patients (mean age, 65.0 ± 8.5 years; 34 men) were evaluated. High pre-therapeutic SUVmax, SUVmean, MTV, and TLG were significantly associated with poor OS based on the likelihood ratio test from univariate Cox regression (all p < 0.05). While pre-therapeutic parameters did not predict PFS, early reductions in volumetric parameters (Δ%MTV and Δ%TLG) on follow-up PET/CT were significantly associated with PFS (p < 0.05). Furthermore, patients exhibiting a "high-to-low" metabolic trajectory from initial staging to pre-therapeutic baseline demonstrated superior PFS compared to the "low-to-high" group (p = 0.02 for SUVmax; p < 0.001 for SUVmean).
conclusionsFDG PET/CT parameters were associated with survival outcomes; pre-therapeutic metabolic burden predicts OS, whereas dynamic metabolic changes and longitudinal trajectory showed associations with PFS in patients treated with chemo-immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.